Bnp Paribas Asset Management Holding S.A. Crinetics Pharmaceuticals, Inc. Transaction History
Bnp Paribas Asset Management Holding S.A.
- $40.4 Billion
- Q3 2024
A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 491,381 shares of CRNX stock, worth $26.5 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
491,381
Previous 546,234
10.04%
Holding current value
$26.5 Million
Previous $24.5 Million
2.63%
% of portfolio
0.06%
Previous 0.06%
Shares
9 transactions
Others Institutions Holding CRNX
# of Institutions
241Shares Held
79.5MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$339 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$336 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$317 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$267 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$241 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.9B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...